ILEU18074 / GMI-1271-301 / Jane Liesveld
Basic Study Information
Purpose:
This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin
antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared
to chemotherapy alone. The safety of uproleselan when given with chemotherapy will
also be investigated in patients with relapsed/refractory AML
Location: University of Rochester Medical Center
Lead Researcher (Principal Investigator)
Lead Researcher:
Jane Liesveld, MD
Study Contact Information
Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search